Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada.
View Top Employees from Ardelyx, Inc.Website | http://www.ardelyx.com |
Ticker | ARDX |
Revenue | $5 million |
Funding | $475 million |
Employees | 299 (226 on RocketReach) |
Founded | 2007 |
Address | 400 Fifth Avenue 210, Waltham, Massachusetts 02451, US |
Phone | (510) 745-1700 |
Fax | (510) 745-0493 |
Technologies |
JavaScript,
HTML,
PHP
+53 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology Research, Biotechnology, Drug Discovery, Healthcare, Science and Engineering, Health Care, Medical |
Web Rank | 6 Million |
Keywords | Biopharmaceuticals, Unmet Medical Needs, Chronic Care |
Competitors | CrystalGenomics, Inc., Loxo Oncology, Otonomy, Inc, Sequella, Inc., Vidac Pharma |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 3254 Companies |
Looking for a particular Ardelyx, Inc. employee's phone or email?
The Ardelyx, Inc. annual revenue was $5 million in 2024.
David Rosenbaum is the Chief Development Officer of Ardelyx, Inc..
226 people are employed at Ardelyx, Inc..
Ardelyx, Inc. is based in Waltham, Massachusetts.
The NAICS codes for Ardelyx, Inc. are [54, 32, 325, 541714, 541, 54171, 5417, 3254].
The SIC codes for Ardelyx, Inc. are [28, 283].